指南与共识呼吸衰竭与机械通气儿科与产科急症

儿童大环内酯类耐药肺炎支原体肺炎诊断与治疗专家共识

Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
指南 / 共识 · World J Pediatr · 2024-08-14
一句话结论29位中国专家制定全球首部儿童MRMP肺炎共识,强调PCR早期识别耐药突变,四环素类和喹诺酮类体外仍敏感、可用于大环内酯类初始治疗失败者。

肺炎支原体是儿童社区获得性肺炎的重要病原,自1968年日本首次报告大环内酯类耐药株以来,MRMP在全球多国出现且发病率不一,MRMP感染导致大环内酯类疗效差、发热迁延、抗生素疗程延长、住院及ICU入住增加、使用糖皮质激素或二线抗生素比例显著升高。2000年以来全球MRMP发病率逐渐上升,东亚尤为突出,但全球尚无儿童MRMP诊治共识。该共识由29位中国儿科呼吸与流行病学专家基于PubMed、Embase、Web of Science、CNKI、Medline和Cochrane Library等数据库证据制定,涵盖流行病学、发病机制、临床表现、早期识别、实验室检查、抗生素使用原则、糖皮质激素与静脉免疫球蛋白应用及支气管镜注意事项。共识指出可通过聚合酶链反应和荧光探针技术在呼吸道标本中早期快速识别MRMP相关基因突变;尽管大环内酯类耐药率仍高,肺炎支原体对四环素类和喹诺酮类等二线抗生素仍保持良好体外敏感性,可作为大环内酯类初始治疗失败者的有效治疗选择。

要点

  • MRMP感染对大环内酯类抗生素反应差,常导致发热迁延、抗生素疗程延长、住院和ICU入住增加、糖皮质激素或二线抗生素使用比例显著升高。
  • 可通过聚合酶链反应和荧光探针技术在呼吸道标本中早期快速识别MRMP相关基因突变。
  • 尽管大环内酯类耐药率仍高,肺炎支原体对四环素类和喹诺酮类等二线抗生素仍保持良好体外敏感性,可作为大环内酯类初始治疗失败者的有效治疗选择。
  • 共识涵盖流行病学、发病机制、临床表现、早期识别、实验室检查、抗生素使用原则、糖皮质激素与静脉免疫球蛋白应用及支气管镜注意事项。
  • 结论指出亟需开展四环素类和喹诺酮类药物在儿童中的进一步研究以评估其对生长发育的影响,并需制定抗生素轮换治疗策略以减少MRMP菌株流行。

适用人群与场景

  • 儿童社区获得性肺炎患者,尤其是大环内酯类抗生素初始治疗失败者。

处置流程与药物剂量

  • 可通过聚合酶链反应和荧光探针技术在呼吸道标本中早期快速识别MRMP相关基因突变。
  • 肺炎支原体对四环素类和喹诺酮类等二线抗生素仍保持良好体外敏感性,可作为大环内酯类抗生素初始治疗失败患者的有效治疗选择。

研究设计与关键结果

  • 由29位中国儿科呼吸与流行病学专家基于证据检索制定,检索数据库包括PubMed、Embase、Web of Science、CNKI、Medline和Cochrane Library。
  • 共识重点涵盖流行病学、发病机制、临床表现、早期识别、实验室检查、抗生素使用原则、糖皮质激素与静脉免疫球蛋白应用及支气管镜注意事项。

证据类型、等级与局限

  • 证据类型:专家共识。
  • 共识基于国际和国内科学证据制定。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对疑似MRMP的儿童肺炎患者,可通过聚合酶链反应和荧光探针技术在呼吸道标本中早期快速识别相关基因突变。
  • 对大环内酯类抗生素初始治疗失败的MRMP肺炎患儿,四环素类和喹诺酮类等二线抗生素仍保持良好体外敏感性,可作为有效治疗选择。
  • 作者认为,亟需开展四环素类和喹诺酮类药物在儿童中的进一步研究以评估其对生长发育的影响,并需制定抗生素轮换治疗策略以减少MRMP菌株流行。

指南或共识出处

  • 儿童大环内酯类耐药肺炎支原体肺炎诊断与治疗专家共识(World J Pediatr)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Mycoplasma pneumoniae (M. pneumoniae) is a significant contributor to community-acquired pneumonia among children. Since 1968, when a strain of M. pneumoniae resistant to macrolide antibiotics was initially reported in Japan, macrolide-resistant M. pneumoniae (MRMP) has been documented in many countries worldwide, with varying incidence rates. MRMP infections lead to a poor response to macrolide antibiotics, frequently resulting in prolonged fever, extended antibiotic treatment, increased hospitalization, intensive care unit admissions, and a significantly higher proportion of patients receiving glucocorticoids or second-line antibiotics. Since 2000, the global incidence of MRMP has gradually increased, especially in East Asia, which has posed a serious challenge to the treatment of M. pneumoniae infections in children and attracted widespread attention from pediatricians. However, there is still no global consensus on the diagnosis and treatment of MRMP in children.

METHODS: We organized 29 Chinese experts majoring in pediatric pulmonology and epidemiology to write the world's first consensus on the diagnosis and treatment of pediatric MRMP pneumonia, based on evidence collection. The evidence searches and reviews were conducted using electronic databases, including PubMed, Embase, Web of Science, CNKI, Medline, and the Cochrane Library. We used variations in terms for "macrolide-resistant", "Mycoplasma pneumoniae", "MP", "M. pneumoniae", "pneumonia", "MRMP", "lower respiratory tract infection", "Mycoplasma pneumoniae infection", "children", and "pediatric".

RESULTS: Epidemiology, pathogenesis, clinical manifestations, early identification, laboratory examination, principles of antibiotic use, application of glucocorticoids and intravenous immunoglobulin, and precautions for bronchoscopy are highlighted. Early and rapid identification of gene mutations associated with MRMP is now available by polymerase chain reaction and fluorescent probe techniques in respiratory specimens. Although the resistance rate to macrolide remains high, it is fortunate that M. pneumoniae still maintains good in vitro sensitivity to second-line antibiotics such as tetracyclines and quinolones, making them an effective treatment option for patients with initial treatment failure caused by macrolide antibiotics.

CONCLUSIONS: This consensus, based on international and national scientific evidence, provides scientific guidance for the diagnosis and treatment of MRMP in children. Further studies on tetracycline and quinolone drugs in children are urgently needed to evaluate their effects on the growth and development. Additionally, developing an antibiotic rotation treatment strategy is necessary to reduce the prevalence of MRMP strains.

来源:World J Pediatr,查看原文。版权归原作者所有。

参考来源

  1. Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2024. PMID: 39143259. doi:10.1007/s12519-024-00831-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。